Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMGP8WX)

Drug Name

ANG-3777 Drug Info

Synonyms

Terevalefim; Refanalin; Terevalefim [INN]; ANG-3777; 1070881-42-3; Terevalefim [USAN]; SNV-003; 500128-99-4; GG91UXK2M5; Terevalefim [USAN:INN]; UNII-GG91UXK2M5; 5-((E)-2-Thiophen-2-yl-vinyl)-lh-pyrazole; 5-[(E)-2-thiophen-2-ylethenyl]-1H-pyrazole; (e)-5-(2-(thiophen-2-yl)vinyl)-1h-pyrazole; WHO 11458; 3-[2-(2-thienyl)ethenyl]-1H-Pyrazole; 1H-Pyrazole, 3-((1E)-2-(2-thienyl)ethenyl)-; BB3; TEREVALEFIM [WHO-DD]; BB-3; SCHEMBL1225335; CHEMBL4650326; SCHEMBL10149623; GTPL11997; ANG3777; GLXC-26914; AKOS040755926; MS-22944; HY-137455; 5-[2-(thiophen-2-yl)ethenyl]-1H-pyrazole; CS-0138662; E80357; (E)-3-(2-(thiophen-2-yl)vinyl)-1H-pyrazole; EN300-7830322; 5-[(E)-2-(thiophen-2-yl)ethenyl]-1H-pyrazole; EN300-18541705

Indication

Disease Entry	ICD 11	Status	REF
Delayed graft function	4B24.0	Phase 3	[1]

Cross-matching ID

PubChem CID: 5714038
TTD Drug ID: DMGP8WX

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatocyte growth factor (HGF)	TT4V2JM	HGF_HUMAN	Mimetic	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Hepatocyte growth factor (HGF)	DTT	HGF	5.784	3.307	4.868	1.926

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Delayed graft function

ICD Disease Classification

4B24.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Hepatocyte growth factor (HGF)	DTT	HGF	4.90E-01	0.13	2.73
Hepatocyte growth factor (HGF)	DTT	HGF	1.98E-07	1.58	2.92

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT02474667) A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of ANG-3777 (Formerly BB3) to Improve Graft Function and Reduce the Severity of Kidney Dysfunction or Delayed Graft Function Following Kidney Transplantation in Recipients of a Deceased Donor Kidney. U.S.National Institutes of Health.
2	Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury. Kidney Int Rep. 2020 Sep 25;5(12):2325-2332.